SOCIETY OF INTERVENTIONAL ONCOLOGY

ACCLAIM Trial Completes Enrollment Eight Months Ahead of Schedule for Colorectal Liver Metastases Study

- The Society of Interventional Oncology's ACCLAIM Trial successfully enrolled 330 tumors in 240 patients with colorectal liver metastases eight months ahead of the enrollment deadline. - This landmark study represents the first global, prospective trial to incorporate objective ablation margin confirmation as a technical endpoint in interventional oncology. - The multi-million-dollar trial involves nine leading cancer centers across the United States and Europe, with funding from Boston Scientific, NeuWave Medical, and Varian. - The primary endpoint aims to determine whether complete margin coverage during microwave ablation correlates with 24-month local tumor progression-free survival.